SG Americas Securities LLC increased its holdings in shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) by 101.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,945 shares of the biopharmaceutical company’s stock after purchasing an additional 16,080 shares during the period. SG Americas Securities LLC’s holdings in Novavax were worth $581,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC acquired a new stake in Novavax during the 2nd quarter worth $47,000. Forsta AP Fonden acquired a new stake in Novavax during the 2nd quarter worth $103,000. US Bancorp DE boosted its stake in Novavax by 9.0% during the 2nd quarter. US Bancorp DE now owns 2,270 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 187 shares during the period. Geneos Wealth Management Inc. boosted its stake in Novavax by 14.4% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,070 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 261 shares during the period. Finally, Virtus ETF Advisers LLC boosted its stake in Novavax by 190.9% during the 2nd quarter. Virtus ETF Advisers LLC now owns 2,679 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 1,758 shares during the period. Institutional investors and hedge funds own 45.70% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Novavax in a research report on Friday, December 2nd. They set a “hold” rating for the company. StockNews.com upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, November 19th. B. Riley cut their price objective on shares of Novavax from $74.00 to $37.00 and set a “buy” rating for the company in a research report on Monday, January 9th. Cowen cut their price objective on shares of Novavax to $55.00 in a research report on Thursday, October 13th. Finally, HC Wainwright cut their price objective on shares of Novavax from $207.00 to $110.00 and set a “buy” rating for the company in a research report on Friday, December 30th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $92.50.
Novavax Trading Down 0.6 %
NASDAQ:NVAX opened at $11.55 on Monday. The firm has a 50-day moving average price of $14.21 and a two-hundred day moving average price of $27.69. Novavax, Inc. has a twelve month low of $8.75 and a twelve month high of $101.39. The company has a market capitalization of $906.72 million, a P/E ratio of -0.67 and a beta of 1.89.
Novavax (NASDAQ:NVAX – Get Rating) last posted its earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($2.15) earnings per share for the quarter, missing the consensus estimate of $2.21 by ($4.36). The business had revenue of $734.58 million for the quarter, compared to analysts’ expectations of $555.50 million. During the same period in the prior year, the business earned ($4.31) EPS. The company’s quarterly revenue was up 310.7% compared to the same quarter last year. On average, equities research analysts predict that Novavax, Inc. will post -7.49 earnings per share for the current year.
Novavax Company Profile
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company’s vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.